ENZYMBI Trademark

Trademark Overview

On Wednesday, February 27, 2019, a trademark application was filed for ENZYMBI with the United States Patent and Trademark Office. The USPTO has given the ENZYMBI trademark a serial number of 88318089. The federal status of this trademark filing is ABANDONED - EXPRESS as of Tuesday, June 4, 2019. This trademark is owned by Samsung Bioepis Co., Ltd.. The ENZYMBI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for medical use, namely, pharmaceutical preparations for immunoregulation, for treatment of autoimmune diseases, for use as anti-cancer agents, for treatment of cancer, for treatment of tumors, for treatment of central nervous system disorders and for treatment of metabolic diseases; pharmaceutical preparations for treating human immune diseases and conditions; pharmaceutical preparations for treating inflammatory diseases and conditions; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for treating rheumatoid arthritis; pharmaceutical preparations for treating psoriatic arthritis; pharmaceutical preparations for treating ankylosing spondylitis; pharmaceutical preparations for treating psoriasis; pharmaceutical preparations for treating polyarticular juvenile idiopathic arthritis; pharmaceutical preparations for treating enthesitis-related arthritis
enzymbi

General Information

Serial Number88318089
Word MarkENZYMBI
Filing DateWednesday, February 27, 2019
Status601 - ABANDONED - EXPRESS
Status DateTuesday, June 4, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for medical use, namely, pharmaceutical preparations for immunoregulation, for treatment of autoimmune diseases, for use as anti-cancer agents, for treatment of cancer, for treatment of tumors, for treatment of central nervous system disorders and for treatment of metabolic diseases; pharmaceutical preparations for treating human immune diseases and conditions; pharmaceutical preparations for treating inflammatory diseases and conditions; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for treating rheumatoid arthritis; pharmaceutical preparations for treating psoriatic arthritis; pharmaceutical preparations for treating ankylosing spondylitis; pharmaceutical preparations for treating psoriasis; pharmaceutical preparations for treating polyarticular juvenile idiopathic arthritis; pharmaceutical preparations for treating enthesitis-related arthritis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, March 19, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSamsung Bioepis Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressIncheon, 21987
KR

Trademark Events

Event DateEvent Description
Tuesday, June 4, 2019ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT
Tuesday, June 4, 2019ABANDONMENT - EXPRESS MAILED
Monday, June 3, 2019TEAS EXPRESS ABANDONMENT RECEIVED
Friday, March 29, 2019NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, March 29, 2019LETTER OF SUSPENSION E-MAILED
Friday, March 29, 2019SUSPENSION LETTER WRITTEN
Friday, March 29, 2019EXAMINER'S AMENDMENT ENTERED
Friday, March 29, 2019NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, March 29, 2019EXAMINERS AMENDMENT E-MAILED
Friday, March 29, 2019EXAMINERS AMENDMENT -WRITTEN
Tuesday, March 26, 2019ASSIGNED TO EXAMINER
Tuesday, March 19, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, March 2, 2019NEW APPLICATION ENTERED IN TRAM

Related Keywords

enzymbi preparations pharmaceutical treating treatment arthritis diseases conditions cancer idiopathic enthesitis